European biotech flourishes as US and Asian capital pours in
Despite benefiting from five times less investment compared with the US, the European biotech sector has blossomed in recent years, attracting increasing financing from a diversified mix of investors and producing several healthcare unicorns. Alessia Argentieri reports
More on Investments
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Trind VC plans up to five early-stage investments in next six months
VC has deployed around 10% of its second, EUR 55m fund and plans to invest in up to 40 startups
Credo Ventures sees activity uptick, plans further deals in 2023 with EUR 75m fourth fund
Czech VC firm's latest vehicle is around 50% deployed and expects to make 25-30 deals in total
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater